198 related articles for article (PubMed ID: 20371467)
1. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
García-Lerma JG; Cong ME; Mitchell J; Youngpairoj AS; Zheng Q; Masciotra S; Martin A; Kuklenyik Z; Holder A; Lipscomb J; Pau CP; Barr JR; Hanson DL; Otten R; Paxton L; Folks TM; Heneine W
Sci Transl Med; 2010 Jan; 2(14):14ra4. PubMed ID: 20371467
[TBL] [Abstract][Full Text] [Related]
2. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
[TBL] [Abstract][Full Text] [Related]
3. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
[TBL] [Abstract][Full Text] [Related]
4. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
García-Lerma JG; Otten RA; Qari SH; Jackson E; Cong ME; Masciotra S; Luo W; Kim C; Adams DR; Monsour M; Lipscomb J; Johnson JA; Delinsky D; Schinazi RF; Janssen R; Folks TM; Heneine W
PLoS Med; 2008 Feb; 5(2):e28. PubMed ID: 18254653
[TBL] [Abstract][Full Text] [Related]
5. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
Kersh EN; Luo W; Adams DR; Mitchell J; Garcia-Lerma JG; Heneine W; Folks TM; Butera S; Otten RA
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):543-6. PubMed ID: 18370590
[TBL] [Abstract][Full Text] [Related]
6. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
Van Rompay KK; Schmidt KA; Lawson JR; Singh R; Bischofberger N; Marthas ML
J Infect Dis; 2002 Nov; 186(10):1508-13. PubMed ID: 12404171
[TBL] [Abstract][Full Text] [Related]
7. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
Cong ME; Youngpairoj AS; Zheng Q; Aung W; Mitchell J; Sweeney E; Hanson DL; Hendry RM; Dobard C; Heneine W; García-Lerma JG
J Virol; 2011 Aug; 85(15):7933-6. PubMed ID: 21632769
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Muñoz de Benito RM; Arribas López JR
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
[TBL] [Abstract][Full Text] [Related]
9. Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Smith MS; Foresman L; Lopez GJ; Tsay J; Wodarz D; Lifson JD; Page A; Wang C; Li Z; Adany I; Buch S; Bischofberger N; Narayan O
Virology; 2000 Nov; 277(2):306-15. PubMed ID: 11080478
[TBL] [Abstract][Full Text] [Related]
10. Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
Subbarao S; Ramos A; Kim C; Adams D; Monsour M; Butera S; Folks T; Otten RA
J Med Primatol; 2007 Aug; 36(4-5):238-43. PubMed ID: 17669212
[TBL] [Abstract][Full Text] [Related]
11. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM
AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761
[TBL] [Abstract][Full Text] [Related]
12. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
13. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Clercq ED
Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
Cong ME; Mitchell J; Sweeney E; Bachman S; Hanson DL; Heneine W; García-Lerma JG
J Infect Dis; 2013 Aug; 208(3):463-7. PubMed ID: 23633402
[TBL] [Abstract][Full Text] [Related]
15. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
Veazey RS; Springer MS; Marx PA; Dufour J; Klasse PJ; Moore JP
Nat Med; 2005 Dec; 11(12):1293-4. PubMed ID: 16273102
[TBL] [Abstract][Full Text] [Related]
16. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates.
Kim CN; Adams DR; Bashirian S; Butera S; Folks TM; Otten RA
J Med Primatol; 2006 Aug; 35(4-5):210-6. PubMed ID: 16872284
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
De Clercq E
Med Res Rev; 2012 Jul; 32(4):765-85. PubMed ID: 22581627
[TBL] [Abstract][Full Text] [Related]
18. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
[TBL] [Abstract][Full Text] [Related]
19. Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Romanelli F; Murphy B
Pharmacotherapy; 2010 Oct; 30(10):1021-30. PubMed ID: 20874040
[TBL] [Abstract][Full Text] [Related]
20. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis.
Kersh EN; Adams DR; Youngpairoj AS; Luo W; Zheng Q; Cong ME; Aung W; Mitchell J; Otten R; Hendry RM; Heneine W; McNicholl J; Garcia-Lerma JG
PLoS One; 2011 Apr; 6(4):e19295. PubMed ID: 21541293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
